Aurora Cannabis Posts Declining Q4 2021 Revenues Of $54.8 Million, Net Loss

Aurora Cannabis (TSX: ACB) this afternoon reported its fourth quarter financial results. The firm reported net revenues of $54.8 million for the quarter, along with a net loss of $134.0 million. For the full fiscal year, the firm posted losses of an astounding $695.1 million.

If investors were searching for a positive in the results, they may have a difficult time finding one. Revenues were down on both a quarter over quarter and year over year basis. Revenues were down 1% from $55.2 million in the third quarter, while revenues fell an incredible 20% on a year over year basis from $68.4 million to the $54.8 million recorded on a net basis – despite the cannabis market as a whole increasing year over year.

The only bright side here, is that medical cannabis sales rose 9% year over year, from $32.2 million to $35.0 million – yet were down quarter over quarter from the $36.4 million recorded last quarter. Consumer cannabis meanwhile was down 45% year over year to $19.5 million, but up 8% quarter over quarter.

Gross margins meanwhile came in at $18.1 million before fair value adjustments, following cost of sales of $37.6 million. Within its news release however, the company was quick to show an “adjusted gross margin” of $30.0 million, after depreciation and inventory impairments were backed out.

Profitability however is still far out of sight for the company, with the firm posting SG&A expenses of $46.9 million, and R&D expenses of $3.0 million during the quarter, along with depreciation and amortization of $23.0 million. This, combined with financing costs of $16.0 million and impairments of intangibles, goodwill and other line items of $98.8 million, lead the company to post a net loss of $134.0 million for the three month period. Adjusted EBITDA meanwhile came in at a negative $19.3 million.

For the full fiscal year, the company managed to post even worse figures. Net revenue came in at $245.3 million, down from the $268.7 million posted in FY2020, while gross margins came in negative at a loss of $12.0 million before adjustments. G&A of $119.4 million, and depreciation and amortization of $49.2 million provided little help here as well, pushing the loss from operations to $282.8 million.

Impairments of PP&E of $282.1 million, legal settlements of $46.2 million, and financing costs of $66.4 million further impacted results, leading to an overall net loss of $695.1 million for the full fiscal year. Adjusted EBITDA meanwhile amounted to a negative $114.1 million.

In terms of balance sheet however, the company currently has $421.5 million in cash, as well as inventory of $117.5 million, with current assets overall pegged at $665.9 million. Payables meanwhile tally up to $57.9 million, while all current liabilities total to $116.4 million.

Despite the losses, things are not looking up for the next quarter. The company during the current quarter closed its Polaris facility in Edmonton, Alberta, while consolidating its R&D operations. The firm reportedly had its impairment occur, at least partially, in the current quarter. Employment also appears to be on a downward slide, with employment declining from 1,761 persons to 1,643 persons as of September 27.

Aurora Cannabis last traded at $8.08 on the TSX.


Information for this briefing was found via Sedar and Aurora Cannabis. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Tariffs Spark New Race for Critical Metals | Rob McEwen

Antimony Resources: The Bald Hill Project

They Laughed at $3,000 Gold, Now We’re Headed for $4,000! | Sean Roosen – Osisko Development Corp.

Recommended

Steadright Begins Preliminary Economic Assessment On TitanBeach Project

Three Miners Trapped Underground At Newmont’s Red Chris Mine

Related News

Aurora Cannabis Caps Rocky Week With Insider Selling 57% of Position

Aurora Cannabis (TSX: ACB) (NYSE: ACB) has had a rough week, and for investors, the...

Friday, December 20, 2019, 10:25:15 PM

Aurora Cannabis: The Analysts Take On The Reliva Acquisition

A week after Aurora Cannabis (TSX: ACB) (NYSE: ACB) closed their U$40 million all-share deal...

Friday, June 5, 2020, 04:08:00 PM

Galaxy Brain: Aurora Charting a Course through the Cannabis Supply Glut

For this weekend’s special piece, Deep Dive author Matthew Cox breaks down the Health Canada...

Saturday, November 23, 2019, 08:36:04 AM

Aurora: Canaccord Raises Price Target To $14.00 On Back Of Earnings

Last night, Aurora Cannabis (TSX: ACB) (NYSE: ACB) reported its second quarter 2020 earnings. They...

Friday, February 12, 2021, 04:02:00 PM

Aurora Cannabis Files For US$300 Million At The Market Financing

Aurora Cannabis (TSX: ACB) (NYSE: ACB) last night announced that it has formally filed a...

Friday, May 21, 2021, 07:21:32 AM